Exercise-Based Management of Diabetic Cardiomyopathy: Preclinical Mechanisms, Clinical Evidence, and Translational Strategies.
- 1Operating Room Department, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
- 2Health Science Center, Yangtze University, Jingzhou, Hubei, China.
Abstract
Diabetic cardiomyopathy is characterized by progressive metabolic dysfunction, myocardial fibrosis, impaired calcium handling, and ventricular remodeling, yet effective strategies for reversing established cardiac injury remain limited. Exercise training has emerged as a promising non-pharmacological approach, although its clinical application is constrained by heterogeneous intervention protocols, inconsistent dose reporting, and limited evidence from well-characterized diabetic cardiomyopathy populations. This narrative review synthesizes current preclinical and clinical evidence on exercise-based management of diabetes-associated myocardial dysfunction, with particular emphasis on underlying mechanisms, exercise prescription, and translational implementation. Experimental studies indicate that exercise may improve myocardial function through enhanced mitochondrial biogenesis and metabolic flexibility, attenuation of oxidative stress and inflammatory-fibrotic signaling, restoration of calcium homeostasis, and regulation of apoptosis, pyroptosis, and microRNA-related pathways. Clinical evidence, derived predominantly from individuals with Type 2 diabetes and subclinical or early cardiac abnormalities, suggests that combined aerobic and resistance training can improve cardiorespiratory fitness, insulin sensitivity, vascular function, and selected indices of left ventricular performance. High-intensity interval training may provide additional benefits in appropriately selected patients, but its safety and effectiveness require individualized assessment. To improve translation, exercise intensity should be reported using physiologically comparable metrics, while treatment response should be evaluated through integrated measures of cardiac imaging, functional capacity, biomarkers, glycemic control, and adverse events. Overall, exercise represents a biologically plausible and clinically relevant adjunctive strategy for diabetic cardiomyopathy, particularly in early-stage disease; however, adequately powered trials in clearly defined patient populations are still needed to establish optimal dose, safety, and long-term cardiovascular benefit.
Related
- Tanshinone IIA in colorectal cancer: preclinical mechanisms, therapeutic sensitization, and translational prospects
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Hepatoprotective natural polyphenol extracts: molecular mechanisms, stabilization-delivery strategies, and translational bottlenecks for functional food applications
- Volatile Anesthetic-Based Combination Strategies Against Ischemia–Reperfusion Injury: Experimental Evidence, Molecular Mechanisms, and Translational Limitations
- Peptides and Peptide Analogues Targeting Acetylcholinesterase-Associated Mechanisms in Alzheimer’s Disease and Dementias: Evidence Gaps, Design Strategies, and Translational Perspectives
BibTeX
@article{li2026exercisebased,
title = {{Exercise-Based Management of Diabetic Cardiomyopathy: Preclinical Mechanisms, Clinical Evidence, and Translational Strategies.}},
author = {Xiaoya Li and Zhiqiang Wang and Jingjing Liu},
journal = {Journal of diabetes},
year = {2026},
month = oct,
doi = {10.1111/1753-0407.70292},
url = {https://europepmc.org/article/MED/42963201},
note = {CC BY},
}
RIS
TY - JOUR
TI - Exercise-Based Management of Diabetic Cardiomyopathy: Preclinical Mechanisms, Clinical Evidence, and Translational Strategies.
AU - Xiaoya Li
AU - Zhiqiang Wang
AU - Jingjing Liu
PY - 2026
DA - 2026/10/30
JO - Journal of diabetes
DO - 10.1111/1753-0407.70292
UR - https://europepmc.org/article/MED/42963201
AB - Diabetic cardiomyopathy is characterized by progressive metabolic dysfunction, myocardial fibrosis, impaired calcium handling, and ventricular remodeling, yet effective strategies for reversing established cardiac injury remain limited. Exercise training has emerged as a promising non-pharmacological approach, although its clinical application is constrained by heterogeneous intervention protocols, inconsistent dose reporting, and limited evidence from well-characterized diabetic cardiomyopathy populations. This narrative review synthesizes current preclinical and clinical evidence on exercise-based management of diabetes-associated myocardial dysfunction, with particular emphasis on underlying mechanisms, exercise prescription, and translational implementation. Experimental studies indicate that exercise may improve myocardial function through enhanced mitochondrial biogenesis and metabolic flexibility, attenuation of oxidative stress and inflammatory-fibrotic signaling, restoration of calcium homeostasis, and regulation of apoptosis, pyroptosis, and microRNA-related pathways. Clinical evidence, derived predominantly from individuals with Type 2 diabetes and subclinical or early cardiac abnormalities, suggests that combined aerobic and resistance training can improve cardiorespiratory fitness, insulin sensitivity, vascular function, and selected indices of left ventricular performance. High-intensity interval training may provide additional benefits in appropriately selected patients, but its safety and effectiveness require individualized assessment. To improve translation, exercise intensity should be reported using physiologically comparable metrics, while treatment response should be evaluated through integrated measures of cardiac imaging, functional capacity, biomarkers, glycemic control, and adverse events. Overall, exercise represents a biologically plausible and clinically relevant adjunctive strategy for diabetic cardiomyopathy, particularly in early-stage disease; however, adequately powered trials in clearly defined patient populations are still needed to establish optimal dose, safety, and long-term cardiovascular benefit.
SN - 1753-0393
SN - 1753-0407
ER -